» Articles » PMID: 22370826

In-house ELISA Method to Analyze Anti-Trypanosoma Cruzi IgG Reactivity for Differential Diagnosis and Evaluation of Chagas Disease Morbidity

Abstract

Introduction: The goal was to develop an in-house serological method with high specificity and sensitivity for diagnosis and monitoring of Chagas disease morbidity.

Methods: With this purpose, the reactivities of anti-T. cruzi IgG and subclasses were tested in successive serum dilutions of patients from Berilo municipality, Jequitinhonha Valley, Minas Gerais, Brazil. The performance of the in-house ELISA was also evaluated in samples from other relevant infectious diseases, including HIV, hepatitis C (HCV), syphilis (SYP), visceral leishmaniasis (VL), and American tegumentary leishmaniasis (ATL), and noninfected controls (NI). Further analysis was performed to evaluate the applicability of this in-house methodology for monitoring Chagas disease morbidity into three groups of patients: indeterminate (IND), cardiac (CARD), and digestive/mixed (DIG/Mix), based on their clinical status.

Results: The analysis of total IgG reactivity at serum dilution 1:40 was an excellent approach to Chagas disease diagnosis (100% sensitivity and specificity). The analysis of IgG subclasses showed cross-reactivity, mainly with NI, VL, and ATL, at all selected serum dilutions. Based on the data analysis, the IND group displayed higher IgG3 levels and the DIG/Mix group presented higher levels of total IgG as compared with the IND and CARD groups.

Conclusions: These findings demonstrated that methodology presents promising applicability in the analysis of anti-T. cruzi IgG reactivity for the differential diagnosis and evaluation of Chagas disease morbidity.

Citing Articles

Risk Factors for Progression to Chronic Chagas Cardiomyopathy: A Systematic Review and Meta-Analysis.

Cutshaw M, Sciaudone M, Bowman N Am J Trop Med Hyg. 2023; 108(4):791-800.

PMID: 36848894 PMC: 10076993. DOI: 10.4269/ajtmh.22-0630.


Accuracy of Diagnostic Tests for the Detection of Chagas Disease: A Systematic Review and Meta-Analysis.

Candia-Puma M, Machaca-Luque L, Roque-Pumahuanca B, Galdino A, Giunchetti R, Ferraz Coelho E Diagnostics (Basel). 2022; 12(11).

PMID: 36359595 PMC: 9689806. DOI: 10.3390/diagnostics12112752.


Rapid diagnostic tests and ELISA for diagnosing chronic Chagas disease: Systematic revision and meta-analysis.

Suescun-Carrero S, Tadger P, Sandoval Cuellar C, Armadans-Gil L, Ramirez Lopez L PLoS Negl Trop Dis. 2022; 16(10):e0010860.

PMID: 36256676 PMC: 9616215. DOI: 10.1371/journal.pntd.0010860.


Insights from the use of erythropoietin in experimental Chagas disease.

de Castro Nobre A, Pimentel C, do Rego G, Paludo G, Pereira Neto G, de Castro M Int J Parasitol Drugs Drug Resist. 2022; 19:65-80.

PMID: 35772309 PMC: 9253553. DOI: 10.1016/j.ijpddr.2022.05.005.


Participation of Central Muscarinic Receptors on the Nervous Form of Chagas Disease in Mice Infected via Intracerebroventricular with Colombian Strain.

de Assis G, Donato M, Milagre M, Bela S, Ricci M, Batista L Pathogens. 2021; 10(2).

PMID: 33503848 PMC: 7922850. DOI: 10.3390/pathogens10020121.